Simeng Wang

All Publications

• The role of respiratory therapy in rib fracture management. Current problems in surgery Anderson, T. N., Wang, S., Free, D., Forrester, J. D. 2024; 61 (12): 101664

  View details for DOI 10.1016/j.cpsurg.2024.101664

  View details for PubMedID 39647970

• Percutaneous cryoneurolysis: new kid on the rib fracture pain 'Block'. Trauma surgery & acute care open Wang, S., Myers, A. A., Forrester, J. D. 2024; 9 (1): e001575

  View details for DOI 10.1136/tsaco-2024-001575

  View details for PubMedID 39296595

  View details for PubMedCentralID PMC11409356

• Percutaneous Cryoneurolysis for Pain Control After Rib Fractures in Older Adults. JAMA surgery Wang, S., Earley, M., Kesselman, A., Vezeridis, A. M., Picel, A. C., Kothary, N., Forrester, J. D. 2024

  View details for DOI 10.1001/jamasurg.2024.2063

  View details for PubMedID 39110467

  View details for PubMedCentralID PMC11307162

• Small bowel obstruction due to a migrated pyloric stent. Trauma surgery & acute care open Agolia, J. P., Wang, S., Fisher, A., Bryan, J. L., Knowlton, L. M. 2024; 9 (1): e001443

  View details for DOI 10.1136/tsaco-2024-001443

  View details for PubMedID 38756695

  View details for PubMedCentralID PMC11097799

• Severe intracranial and intra-abdominal hemorrhage: timing is everything. Trauma surgery & acute care open Farooqi, N. B., Wong, S. Y., Wang, S., Knowlton, L. M. 2024; 9 (1): e001434

  View details for DOI 10.1136/tsaco-2024-001434

  View details for PubMedID 38616787

  View details for PubMedCentralID PMC11015236

• Prolonged Ischemia Increases Complications Among High- and Low-Volume Centers in Lung Transplantation ANNALS OF THORACIC SURGERY Wadowski, B. J., Wang, S., Angel, L. F., Geraci, T. C., Chan, J. Y., Chang, S. H. 2023; 116 (2): 374-381

  Abstract

  The effect of prolonged allograft ischemic time on lung transplant outcomes remains controversial, with most studies associating it with increased mortality, but this effect is partly mitigated by center volume. This study sought to evaluate the mechanism of these findings and clarify the impact of ischemic time on short-term outcomes in a national sample.Data on lung transplants (January 2010-Janary 2017) were extracted from the Scientific Registry of Transplant Recipients database. Ischemic time was dichotomized as prolonged ischemic time (PIT) or no PIT (N-PIT) at 6 hours. High-volume centers were defined as the top quintile. The primary outcome was 30-day, 1-year, and 3-year mortality; secondary outcomes included in-hospital complications and 72-hour oxygenation.Among 11,809 records, there were significant differences between PIT and N-PIT recipients by demographics, lung allocation score, and donor organ metrics. In a 1:1 propensity score-matched cohort (n = 6422), PIT recipients had reduced survival compared with N-PIT at 3 years (66.5% vs 68.8%, P = .031). On multivariable analysis, this effect persisted among low-volume but not high-volume centers. PIT recipients were more likely to require reintubation, prolonged (>5 days) mechanical ventilation, hemodialysis, longer stay, and acute rejection (all P < .01). Except for reintubation, these disparities were present at both high- and low-volume centers independently. Ischemic time had no effect on 72-hour oxygenation.PIT remains associated with higher rates of postoperative complications and reduced short-term survival. While center volume ameliorated the survival impact, this was not achieved by reducing postoperative complications. Further research is warranted before broadening ischemic time thresholds among low-volume centers.

  View details for DOI 10.1016/j.athoracsur.2022.10.018

  View details for Web of Science ID 001051261500001

  View details for PubMedID 37489398

• Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma ONCOTARGET Eberhardt, A., Hansen, J. N., Koster, J., Lotta, L. T., Wang, S., Livingstone, E., Qian, K., Valentijn, L. J., Zheng, Y., Schor, N. F., Li, X. 2016; 7 (39): 63629-63639

  Abstract

  Amplification or overexpression of MYCN is associated with poor prognosis of human neuroblastoma. We have recently defined a MYCN-dependent transcriptional signature, including protein arginine methyltransferase 1 (PRMT1), which identifies a subgroup of patients with high-risk disease. Here we provide several lines of evidence demonstrating PRMT1 as a novel regulator of MYCN and implicating PRMT1 as a potential therapeutic target in neuroblastoma pathogenesis. First, we observed a strong correlation between MYCN and PRMT1 protein levels in primary neuroblastoma tumors. Second, MYCN physically associates with PRMT1 by direct protein-protein interaction. Third, depletion of PRMT1 through siRNA knockdown reduced neuroblastoma cell viability and MYCN expression. Fourth, we showed that PRMT1 regulates MYCN stability and identified MYCN as a novel substrate of PRMT1. Finally, we demonstrated that mutation of putatively methylated arginine R65 to alanine decreased MYCN stability by altering phosphorylation at residues serine 62 and threonine 58. These results provide mechanistic insights into the modulation of MYCN oncoprotein by PRMT1, and suggest that targeting PRMT1 may have a therapeutic impact on MYCN-driven oncogenesis.

  View details for DOI 10.18632/oncotarget.11556

  View details for Web of Science ID 000387167800063

  View details for PubMedID 27571165

  View details for PubMedCentralID PMC5325390